Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks

BACKGROUND: Tenofovir disoproxil fumarate (TDF) is a prodrug of a nucleotide analogue. As an antiviral drug, TDF has been proposed in the first-line treatment of chronic hepatitis B (CHB). Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd., and Viread,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Fan, Fan, Ya-Nan, Si, Chong-Wen, Yu, Yan-Yan, Shang, Jia, Yu, Zu-Jiang, Mao, Qing, Xie, Qing, Zhao, Wei, Li, Jun, Gao, Zhi-Liang, Wu, Shan-Ming, Tang, Hong, Cheng, Jun, Chen, Xin-Yue, Zhang, Wen-Hong, Wang, Hao, Xu, Zhong-Nan, Wang, Ling, Dai, Jun, Xu, Jing-Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Randomized Controlled Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223849/
https://www.ncbi.nlm.nih.gov/pubmed/34222435
http://dx.doi.org/10.12998/wjcc.v9.i18.4690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223849/
https://www.ncbi.nlm.nih.gov/pubmed/34222435
http://dx.doi.org/10.12998/wjcc.v9.i18.4690

Ejemplares similares